Lung Transplant; Complications Clinical Trial
Official title:
Observational, Epidemiological, Retrospective Study of the Management of CMV Infection in a Cohort of Patients Receiving Lung Transplantation in Spain
Background: Lung transplant recipients (LTR) have the highest risk of CMV infection. CMV
pneumonitis, lymphocytic bronchitis, and detection of CMV DNA in bronchoalveolar lavage fluid
are independent risk factors for the development of chronic lung allograft dysfunction
(CLAD). However, to demonstrate the clinical impact of the indirect effects of CMV, it is
necessary to conduct studies with a very large sample size.
Hypothesis: The different current preventive strategies for CMV infection in LTR and their
clinical application on a daily basis impact on the development of direct and indirect
effects of CMV in this population.
Objectives: To study the effect of CMV infection on LTR in relation to current preventive
strategies in terms of:
- The incidence of acute and chronic rejection
- The incidence of other opportunistic infections
- The incidence of neoplastic disease, especially, post-transplant lymphoproliferative
disease
- Patient and graft survival Methods: Multicenter, retrospective, cohort study.
Consecutive inclusion of all adult lung transplant recipients from 2013 to 2017 with 2
years of follow-up. The investigators will collect and analyze the main clinical and
microbiological variables in order to respond to the objectives of the study.
Relevance: Knowing in detail the current epidemiology of CMV infection in LTR and its
subsequent influence on both mortality and the presence of different complications, could
allow improving the management of these patients in the future.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05526950 -
Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb)
|
N/A | |
Recruiting |
NCT05916495 -
An Evaluation of Remote Care (Questionnaire+Hybrid) in Patients Who Are Post-lung Transplant
|
N/A | |
Enrolling by invitation |
NCT05950724 -
RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant
|
Early Phase 1 | |
Active, not recruiting |
NCT05505422 -
Routine Versus Selective Intraoperative ECMO in Lung Transplant
|
N/A | |
Recruiting |
NCT05081141 -
HHV8 and Solid Organ Transplantation
|
||
Enrolling by invitation |
NCT04522388 -
Examining the Effect of Nutritional Supplementation on Skeletal Muscle Mass in Patients Awaiting Lung Transplant
|
N/A | |
Completed |
NCT04165161 -
Performance Diagnosis of a Patent Foramen Ovale During Lung Transplantation Using Transesophageal Echocardiography
|
N/A | |
Recruiting |
NCT05050955 -
AlloSure Lung Assessment and Metagenomics Outcomes Study
|
||
Withdrawn |
NCT03258801 -
Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis
|
||
Completed |
NCT04892719 -
4DX Functional Lung Imaging in the Diagnosis of Chronic Lung Allograft Dysfunction After Lung Transplantation
|
N/A | |
Completed |
NCT03221764 -
Intraoperative Amiodarone to Prevent Atrial Fibrillation in Lung Transplant Patients
|
Phase 2 | |
Active, not recruiting |
NCT04975607 -
Live Music Therapy to Reduce Anxiety, Pain and Improve Sleep in Post-Operative Lung Transplant Patients: A Pilot Study
|
N/A | |
Completed |
NCT05116748 -
COVID19 Vaccine in SOT Adult Recipients
|
||
Recruiting |
NCT03367221 -
Physiological Response in Lung Transplant Recipients Undergoing Neurally Adjusted Ventilatory Assist
|
N/A | |
Recruiting |
NCT03276403 -
Primary Graft Dysfunction Score in Lung Transplantation
|
N/A | |
Active, not recruiting |
NCT03656926 -
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)
|
Phase 3 | |
Completed |
NCT05242289 -
Cytokine Adsorption in Lung Transplantation
|
N/A | |
Recruiting |
NCT04837339 -
Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation
|
N/A | |
Not yet recruiting |
NCT06399302 -
Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
|
||
Terminated |
NCT03562416 -
Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects
|
Phase 2 |